MedTrace Logo

Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder

NCT04188392 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-08-31

Study results available
· View outcomes & findings →

Summary

This preliminary, open-label study assesses the feasibility of 34mg at bedtime for 6 weeks in Veterans with Posttraumatic Stress Disorder and insomnia.

Conditions

  • Post-traumatic Stress Disorder
  • Insomnia

Interventions

DRUG

Pimavanserin

pimavanserin tablet

Sponsors & Collaborators

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Melissa B Jones, MD · Michael E. DeBakey VA Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2021-10-27
Completion
2021-11-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04188392 on ClinicalTrials.gov